Implanet Confirms its PME-PEA Equity Savings Plan Eligibility

Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729), a medical technology company specializing in vertebral and knee-surgery implants, today confirmed that its shares are eligible for the new "PEA-PME” SME equity savings plan.

IMPLANET meets the eligibility criteria for "PEA-PME” SME equity savings plans in compliance with Decree n°2014-283 issued on March 4, 2014 relating to the application of article 70 of the 2014 finance law n° 2013-1278:

• a workforce of less than 5,000 staff;
• annual revenue of less than €1,500m or a balance sheet of less than €2,000m.

Investors can include IMPLANET shares in PEA-PME savings accounts, a new plan aimed at encouraging investments in small and mid-cap companies:

• identical terms and conditions for opening a new account as the existing equity savings plan (PEA) accounts;
• ceiling set at €75,000;
• individuals can hold PEA-PME savings account in a different financial institution than where they hold an existing PEA account;
• same tax incentives as PEA equity savings plan.

Next financial press release: Q1 2014 revenue, on 28 April 2014

About IMPLANET
Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. IMPLANET’s proven orthopedic platform, based on perfectly controlling the traceability of its products, gives the Company the proven ability to enhance this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory approval from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 35 staff and recorded 2013 sales of €6.7 million.

For further information, please visit www.implanet.com